Is Tango Therapeutics, Inc. (NASDAQ:TNGX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tango Therapeutics, Inc. at current levels.
Synthetic lethality finally delivering readable data, with three shots on goal in MTAP-deleted tumors that the market still treats as one bet.
Where TNGX is headed
By the back half of 2027, Tango should no longer be filed in investor minds as 'the synthetic lethality story'. It should be filed as the company that owns the MTAP-deletion franchise, a roughly 10-15% slice of solid tumors that nobody else has cracked at scale. TNG462 is the lead horse. If the Phase 1/2 update at ESMO or ASH this year shows durable responses in pancreatic and NSCLC patients at tolerable doses, Tango stops being compared to its own past and starts being compared to AMG 193 and the broader MTA-cooperative PRMT5 cohort. With around $300m of cash, a partnership economic split with Gilead on the discovery engine, and a real shot at a registrational path in second-line MTAP-null pancreatic by 2028, the platform finally pays rent.
Read the full Compass Direction on TNGX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $20.24).
See the full TNGX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Tango Therapeutics, Inc. (NASDAQ:TNGX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tango Therapeutics, Inc. at current levels. Synthetic lethality finally delivering readable data, with three shots on goal in MTAP-deleted tumors that the market still treats as one bet.
What is TNGX's Compass Score?
Tango Therapeutics, Inc. scores 75/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TNGX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TNGX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.